Frequency of liver test increases on abiraterone acetate in men with castrate-resistant prostate cancer (CRPC): Natural history, management, and outcome.

被引：0
|
作者：
Colomba, Emeline
Marret, Gregoire
Baciarello, Giulia
Massard, Christophe
Loriot, Yohann
Albiges, Laurence
Carton, Edith
Alexandre, Jerome
Huillard, Olivier
Culine, Stephane
Fizazi, Karim
机构：
[1] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[2] St Louis Hosp, Paris, France
[3] Gustave Roussy Canc Campus, Villejuif, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Univ Paris 05, Hop Cochin, CARPEM, AP HP, Paris, France
[6] Paris Descartes Univ, Cochin Hosp, Immunomodulatory Therapies Multidisciplinary Stud, AP HP,CARPEM, Paris, France
[7] Hosp St Louis, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world experience with sipuleucel-T (Sip-T) in Asian men with castrate-resistant prostate cancer (CRPC).
    Zhang, Jingsong
    Liu, Ming
    Pan, Jiahua
    Wei, Xiao X.
    Harmon, Matthew
    Azzolina, John
    Flanders, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)
    Espana Fernandez, S.
    Piulats, J. M.
    Sala, N.
    Velarde, J. M.
    Ferrandiz, U.
    Etxaniz Ulazia, O.
    Heras Lopez, L.
    Barretina Ginesta, M. P.
    Garcia del Muro, X.
    Font, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Hansen, Aaron Richard
    Joshua, Anthony M.
    Warde, Padraig Richard
    Gregg, Richard William
    Fleshner, Neil Eric
    Tomlinson, George
    Hotte, Sebastien J.
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
    Gupta, Santosh
    Halabi, Susan
    Yang, Qian
    Roy, Akash
    Tubbs, Alisa
    Gore, Yamini
    George, Daniel J.
    Nanus, David M.
    Antonarakis, Emmanuel S.
    Danila, Daniel C.
    Szmulewitz, Russell Z.
    Wenstrup, Richard
    Armstrong, Andrew J.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1929 - 1937
  • [45] Does Pretreatment with Abiraterone Acetate (AA) Or Enzlutamide (ENZA) Affect the Efficacy of Subsequent Cabazitaxel Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)?
    Body, A.
    Pranavan, G.
    Malik, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 56 - 56
  • [46] Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Heo, Mi Hwa
    Park, Se Hoon
    Kim, Hee Kyung
    Cho, Jinhyun
    Kim, Youjin
    Lee, Hansang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [47] REDUCED DOSE ABIRATERONE ACETATE WITH CONCOMITANT LOW DOSE PREDNISONE IN THE TREATMENT OF ≥85 YEARS AGED PATIENTS WITH ADVANCED CASTRATE-RESISTANT PROSTATE CANCER
    Roviello, Giandomenico
    Francini, Edoardo
    Fiaschi, Anna Ida
    Laera, Letizia
    Miano, Salvatora Tindara
    Petrioli, Roberto
    ANTICANCER RESEARCH, 2015, 35 (06) : 3633 - 3633
  • [48] Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
    Francolini, Giulio
    Allegra, Andrea Gaetano
    Detti, Beatrice
    Di Cataldo, Vanessa
    Caini, Saverio
    Bruni, Alessio
    Ingrosso, Gianluca
    D'Angelillo, Rolando Maria
    Alitto, Anna Rita
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Facchini, Gaetano
    Banini, Marco
    Simontacchi, Gabriele
    Desideri, Isacco
    Meattini, Icro
    Valicenti, Richard K.
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5561 - +
  • [49] PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
    Layton, Jodi Lyn
    Manogue, Charlotte
    Light, Malcolm
    Jaeger, Ellen
    Cotogno, Patrick
    Ledet, Elisa Marie
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, Oliver A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [50] Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Cotogno, Patrick
    Ledet, Elisa M.
    Steinberger, Allie E.
    Chowdry, Rajasree Pia
    Stolten, Michael
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345